Devra Olson

6PUBLICATIONS
89CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityGlycoconjugates
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 28, 2026
PF-08046876, a differentiated integrin beta-6 antibody-drug conjugate delivering a potent camptothecin payload optimized for bystander effect and reduced drug efflux.

|Apr 20, 2026
An Integrin β6-targeted antibody-drug conjugate optimized for intravesical delivery to treat non-muscle invasive bladder cancer.

|Oct 29, 2025
Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models.

David R Gruber, Elizabeth J Cummins, Weiping Zeng

|Apr 28, 2025
PF-08046032: A Novel, Investigational CD25-Directed Antibody-Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors.

Sherif Abdelhamed, Xinqun Zhang, Weiping Zeng

|Sep 18, 2023
HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer.

Devra Olson, Janelle Taylor, Kelsi Willis

|Feb 17, 2023
SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models.

Rebecca Mazahreh, Marsha L Mason, John J Gosink

Pageof 1

Frequent Collaborators

4 joint publications

Rebecca Mazahreh

3 joint publications

Kelly M Hensley

2 joint publications

Weiping Zeng

2 joint publications

Robert Thurman